Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes

Journal of Drug Targeting

Volumn 14, Issue 4, 2006, Pages 225-232

  Arima, Hidetoshi ^a   Hagiwara, Yoshiyuki ^a   Hirayama, Fumitoshi ^a   Uekama, Kaneto ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

cyclodextrin; Antitumor effect; Doxorubicin; Inclusion complex; Liposome; Residence time

Indexed keywords

DOXORUBICIN; GAMMA CYCLODEXTRIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; COLON TUMOR; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; GROWTH INHIBITION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TISSUE DISTRIBUTION; TUMOR GROWTH;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GAMMA-CYCLODEXTRINS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 33745268193     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600711136     Document Type: Article

References (38)

1. Bekers, O and Beijnen, JH and Otagiri, M and Bult, A and Underberg, WJ. (1990) Inclusion complexation of doxorubicin and daunorubicin with cyclodextrins J Pharm Biomed Anal, 8, pp. 671-674.
2. Ceh, B and Winterhalter, M and Frederik, PM and Vallner, JJ and Lasic, DD. (1997) Stealth liposomes: From theory to product Adv Drug Deliv Rev, 24, pp. 165-177.
3. Chakraborty, KK and Naik, SR. (2003) Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin-B complexed with different chemically modified β-cyclodextrins J Pharm Pharm Sci, 6, pp. 231-237.
4. Charrois, GJ and Allen, TM. (2004) Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer Biochim Biophys Acta, 1663, pp. 167-177.
5. Corbett, TH and Griswold, DP, Jr and Roberts, BJ and Peckham, JC and Schabel, FM, Jr. (1978) Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy Cancer Treat Rep, 62, pp. 1471-1488.
6. Crommelin, DJ and Storm, G. (2003) Liposomes: From the bench to the bed J Liposome Res, 13, pp. 33-36.
7. Fatouros, DG and Hatzidimitriou, K and Antimisiaris, SG. (2001) Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: Comparison of membrane integrity and drug release Eur J Pharm Sci, 13, pp. 287-296.
8. Gabizon, A and Goren, D and Cohen, R and Barenholz, Y. (1998) Development of liposomal anthracyclines: From basics to clinical applications J Control Release, 53, pp. 275-279.
9. Ganapathi, R and Krishan, A. (1984) Effect of cholesterol content of liposomes on the encapsulation, efflux and toxicity of adriamycin Biochem Pharmacol, 33, pp. 698-700.
10. Hagiwara, Y and Arima, H and Hirayama, F and Uekama, K. (2006a) Prolonged retention of doxorubicin in tumor cells by encapsulation of γ-cyclodextrin complex in pegylated liposomes J Incl Phenom Macrocycl Chem. In press
11. Hagiwara, Y and Arima, H and Hirayama, F and Uekama, K. (2006b) Preparation and pharmaceutical evaluation of liposomes entrapping salicylic acid/gamma-cyclodextrin conjugate Chem Pharm Bull, 54, pp. 26-32.
12. Hu, YP and Henry-Toulme, N and Robert, J. (1995) Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells Eur J Cancer, 31A, pp. 389-394.
13. Irie, T and Uekama, K. (1997) Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J Pharm Sci, 86, pp. 147-162.
14. Klibanov, AL and Maruyama, K and Torchilin, VP and Huang, L. (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett, 268, pp. 235-237.
15. Laginha, KM and Verwoert, S and Charrois, GJ and Allen, TM. (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors Clin Cancer Res, 11, pp. 6944-6949.
16. Lim, HJ and Masin, D and Mcintosh, NL and Madden, TD and Bally, MB. (2000) Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors J Pharmacol Exp Ther, 292, pp. 337-345.
17. Maestrelli, F and Gonzalez-Rodriguez, ML and Rabasco, AM and Mura, P. (2005) Preparation and characterisation of liposomes encapsulating ketoprofen-cyclodextrin complexes for transdermal drug delivery Int J Pharm, 298, pp. 55-67.
18. Masuike, T and Odake, J and Kohagura, M and Noda, T and Takemoto, Y. (1984) Determination of adriamycin and its metabolites in biological samples using high performance liquid chromatography. II. Analysis of tissues by extraction method Yakugaku Zasshi, 104, pp. 620-623.
19. Matsumura, Y and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res, 46, pp. 6387-6392.
20. Mayer, LD and Hope, MJ and Cullis, PR. (1986a) Vesicles of variable sizes produced by a rapid extrusion procedure Biochim Biophys Acta, 858, pp. 161-168.
21. Mayer, LD and Bally, MB and Cullis, PR. (1986b) Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim Biophys Acta, 857, pp. 123-126.
22. McCormack, B and Gregoriadis, G. (1994a) Drug-in-cyclodextrins-in liposomes: A novel concept in drug delivery Int J Pharm, 112, pp. 249-258.
23. McCormack, B and Gregoriadis, G. (1994b) Entrapment of cyclodextrin-drug complexes into liposomes: Potential advantages in drug delivery J Drug Target, 2, pp. 449-454.
24. McCormack, B and Gregoriadis, G. (1996) Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-β-cyclodextrin/drug complexes after intravenous injection into rats: Implications in drug delivery Biochim Biophys Acta, 1291, pp. 237-244.
25. Medina, OP and Zhu, Y and Kairemo, K. (2004) Targeted liposomal drug delivery in cancer Curr Pharm Des, 10, pp. 2981-2989.
26. Nishijo, J and Mizuno, H. (1998) Interactions of cyclodextrins with DPPC liposomes. Differential scanning calorimetry studies Chem Pharm Bull, 46, pp. 120-124.
27. Papahadjopoulos, D and Allen, TM and Gabizon, A and Mayhew, E and Matthay, K and Huang, SK and Lee, KD and Woodle, MC and Lasic, DD and Redemann, C and Martin, FJ. (1991) Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA, 88, pp. 11460-11464.
28. Park, JW. (2002) Liposome-based drug delivery in breast cancer treatment Breast Cancer Res, 4, pp. 95-99.
29. Park, JW and Hong, K and Kirpotin, DB and Colbern, G and Shalaby, R and Baselga, J and Shao, Y and Nielsen, UB and Marks, JD and Moore, D and Papahadjopoulos, D and Benz, CC. (2002) Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery Clin Cancer Res, 8, pp. 1172-1181.
30. Pick, U. (1981) Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures Arch Biochem Biophys, 212, pp. 186-194.
31. Sapra, P and Tyagi, P and Allen, TM. (2005) Ligand-targeted liposomes for cancer treatment Curr Drug Deliv, 2, pp. 369-381.
32. Uekama, K and Hirayama, F and Irie, T. (1998) Cyclodextrin drug carrier systems Chem Rev, 98, pp. 2045-2076.
33. Uekama, K. (2004) Design and evaluation of cyclodextrin-based drug formulation Chem Pharm Bull, 52, pp. 900-915.
34. Unezaki, S and Maruyama, K and Ishida, O and Suginaka, A and Hosoda, J and Iwatsuru, M. (1995) Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathis poly(ethylene glycol) Int J Pharm, 126, pp. 41-48.
35. Vertut-Doi, A and Ishiwata, H and Miyajima, K. (1996) Binding and uptake of liposomes containing a poly(ethylene glycol) derivative of cholesterol (stealth liposomes) by the macrophage cell line J774: Influence of PEG content and its molecular weight Biochim Biophys Acta, 1278, pp. 19-28.
36. Willis, M and Forssen, E. (1998) Ligand-targeted liposomes Adv Drug Deliv Rev, 29, pp. 249-271.
37. Xiong, XB and Huang, Y and Lu, WL and Zhang, H and Zhang, X and Zhang, Q. (2005a) Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improvedantitumor activity in vivo Pharm Res, 22, pp. 933-939.
38. Xiong, XB and Huang, Y and Lu, WL and Zhang, X and Zhang, H and Nagai, T and Zhang, Q. (2005b) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic J Control Release, 107, pp. 262-275.